Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal
Daxor Corporation (DXR) announced significant findings from a Duke University Medical Center study published in the American Heart Journal regarding Blood Volume Analysis (BVA) in heart failure patients. The research demonstrates BVA's effectiveness in differentiating between true and dilutional anemia in heart failure patients.
Key findings revealed that among heart failure patients diagnosed with anemia, 60% had true anemia while 40% had dilutional pseudo-anemia. Patients with dilutional pseudo-anemia showed higher tendencies toward heart failure hospitalization. The study also found that heart failure patients with red blood cell mass deficit or true anemia demonstrated poorer exercise capacity.
The research validates BVA's importance in heart failure management, as standard blood panels are not sufficiently sensitive or specific for this purpose.
Daxor Corporation (DXR) ha annunciato risultati significativi da uno studio condotto dal Duke University Medical Center pubblicato sull'American Heart Journal riguardante l'Analisi del Volume Sanguigno (BVA) nei pazienti con insufficienza cardiaca. La ricerca dimostra l'efficacia della BVA nel distinguere tra anemia vera e anemia da diluizione nei pazienti con insufficienza cardiaca.
I risultati principali hanno rivelato che tra i pazienti con insufficienza cardiaca diagnosticati con anemia, il 60% presentava anemia vera mentre il 40% soffriva di pseudo-anemia da diluizione. I pazienti con pseudo-anemia da diluizione mostravano una maggiore tendenza a ricoveri per insufficienza cardiaca. Lo studio ha inoltre evidenziato che i pazienti con deficit di massa eritrocitaria o anemia vera avevano una capacità di esercizio ridotta.
La ricerca conferma l'importanza della BVA nella gestione dell'insufficienza cardiaca, poiché i pannelli ematici standard non sono sufficientemente sensibili o specifici per questo scopo.
Daxor Corporation (DXR) anunció hallazgos importantes de un estudio del Duke University Medical Center publicado en el American Heart Journal sobre el Análisis del Volumen Sanguíneo (BVA) en pacientes con insuficiencia cardíaca. La investigación demuestra la efectividad del BVA para diferenciar entre anemia verdadera y anemia por dilución en pacientes con insuficiencia cardíaca.
Los hallazgos clave revelaron que, entre los pacientes con insuficiencia cardíaca diagnosticados con anemia, el 60% tenía anemia verdadera mientras que el 40% presentaba pseudoanemia por dilución. Los pacientes con pseudoanemia por dilución mostraron una mayor tendencia a hospitalizaciones por insuficiencia cardíaca. El estudio también encontró que los pacientes con insuficiencia cardíaca y déficit de masa eritrocitaria o anemia verdadera presentaban una capacidad de ejercicio reducida.
La investigación valida la importancia del BVA en el manejo de la insuficiencia cardíaca, ya que los paneles sanguíneos estándar no son suficientemente sensibles ni específicos para este propósito.
Daxor Corporation(DXR)는 American Heart Journal에 발표된 Duke University Medical Center 연구의 중요한 결과를 발표했습니다. 이 연구는 심부전 환자에서 혈액량 분석(BVA)이 진성 빈혈과 희석성 빈혈을 구분하는 데 효과적임을 보여줍니다.
주요 결과에 따르면, 빈혈로 진단된 심부전 환자 중 60%는 진성 빈혈이며 40%는 희석성 가성 빈혈을 보였습니다. 희석성 가성 빈혈 환자는 심부전으로 인한 입원 경향이 더 높았습니다. 또한, 적혈구 질량 결핍이나 진성 빈혈을 가진 심부전 환자는 운동 능력이 저하된 것으로 나타났습니다.
이 연구는 표준 혈액 검사 패널이 이 목적에 충분히 민감하거나 특이하지 않기 때문에 심부전 관리에서 BVA의 중요성을 입증합니다.
Daxor Corporation (DXR) a annoncé des résultats importants issus d'une étude du Duke University Medical Center publiée dans l'American Heart Journal concernant l'analyse du volume sanguin (BVA) chez les patients souffrant d'insuffisance cardiaque. La recherche démontre l'efficacité de la BVA pour différencier l'anémie vraie de l'anémie par dilution chez ces patients.
Les résultats clés ont révélé que parmi les patients atteints d'insuffisance cardiaque diagnostiqués avec une anémie, 60 % présentaient une anémie vraie tandis que 40 % souffraient d'une pseudo-anémie par dilution. Les patients avec une pseudo-anémie par dilution avaient une tendance accrue aux hospitalisations pour insuffisance cardiaque. L'étude a également montré que les patients avec un déficit de masse globulaire rouge ou une anémie vraie avaient une capacité d'exercice réduite.
Cette recherche confirme l'importance de la BVA dans la prise en charge de l'insuffisance cardiaque, les analyses sanguines standards n'étant pas suffisamment sensibles ni spécifiques pour cet usage.
Daxor Corporation (DXR) gab bedeutende Ergebnisse einer Studie des Duke University Medical Center bekannt, die im American Heart Journal veröffentlicht wurde und die Blutvolumenanalyse (BVA) bei Herzinsuffizienzpatienten untersucht. Die Forschung zeigt die Wirksamkeit der BVA bei der Unterscheidung zwischen echter und verdünnter Anämie bei Herzinsuffizienzpatienten.
Die wichtigsten Ergebnisse zeigten, dass unter den Herzinsuffizienzpatienten mit Anämiediagnose 60 % echte Anämie hatten, während 40 % eine verdünnte Pseudoanämie aufwiesen. Patienten mit verdünnter Pseudoanämie zeigten eine höhere Tendenz zu Krankenhausaufenthalten aufgrund von Herzinsuffizienz. Die Studie ergab außerdem, dass Herzinsuffizienzpatienten mit einem Mangel an roten Blutkörperchen oder echter Anämie eine schlechtere Belastungskapazität aufwiesen.
Die Forschung bestätigt die Bedeutung der BVA im Management der Herzinsuffizienz, da Standard-Blutuntersuchungen für diesen Zweck nicht ausreichend sensitiv oder spezifisch sind.
- Study validates BVA technology's effectiveness in differentiating anemia types in heart failure patients
- Research published in prestigious American Heart Journal adds credibility to Daxor's technology
- BVA addresses a key requirement in Heart Failure Guidelines by major cardiovascular societies
- None.
Insights
Duke study validates Daxor's BVA technology for accurately identifying anemia types in heart failure, potentially improving treatment decisions and outcomes.
This Duke University research published in the American Heart Journal represents a significant clinical validation for Daxor's Blood Volume Analysis (BVA) technology. The study addresses a critical clinical challenge: accurately differentiating between true anemia (requiring red cell therapy) and dilutional pseudo-anemia (which doesn't) in heart failure patients – something standard hemoglobin measurements cannot accomplish.
The findings reveal that among heart failure patients diagnosed with anemia by conventional WHO criteria,
The study also identified that patients with RBCM deficit or true anemia demonstrated poorer exercise capacity, and those with dilutional pseudo-anemia showed a tendency toward higher heart failure hospitalization rates. These clinical correlations provide physicians with actionable insights that could influence therapeutic decisions.
From a market perspective, this research strengthens Daxor's position by addressing a specific, guideline-recommended aspect of heart failure management that current diagnostic methods cannot adequately fulfill. By enabling precision in volume status assessment, BVA offers a pathway to improved heart failure management, potentially reducing hospitalizations and improving functional outcomes for patients. This publication in a prestigious journal adds considerable scientific credibility to the company's technology and its clinical utility in cardiovascular care.
Published Research Demonstrates the Value of BVA in Meeting Key Goal of Identifying Anemia in Heart Failure Patients
Oak Ridge, TN, May 14, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor Corporation, the global leader in blood volume measurement technology, today announces significant new findings from Duke University Medical Center published in the prestigious American Heart Journal. The research demonstrates how Blood Volume Analysis (BVA) enables precise measurement of red blood cell mass (RBCM) and effectively differentiates between true and dilutional anemia in heart failure (HF) patients.
The detection of true anemia and its management is a key part of Heart Failure Guidelines published by cardiovascular societies, including the American College of Cardiology and the Heart Failure Society of America, but standard blood panels of hematocrit and hemoglobin levels are not sensitive or specific to enable care for this key objective.
The study, titled, "Relationship of Red Blood Cell Mass Profiles and Anemia Type to Outcomes and Cardiopulmonary Exercise Performance in Chronic Heart Failure," highlights the connections between RBCM profiles using BVA, different anemia types, heart failure outcomes, and cardiopulmonary exercise test (CPET) parameters.
Dr. Veraprapas Kittipibul, the study's lead investigator, outlined key findings:
- Anemia is prevalent in heart failure patients and can be categorized by type using BVA.
- Among heart failure patients diagnosed with anemia by WHO hemoglobin criteria,
60% had true anemia while40% had dilutional pseudo-anemia. (Only truly anemic patients need red cell therapy while pseudo-anemic patients do not, yet WHO criteria does not differentiate this need.) - Patients with dilutional pseudo-anemia.showed a tendency toward higher heart failure hospitalization compared to those with no anemia or true anemia.
- No significant difference in heart failure hospitalization rates was observed across different RBCM profiles.
- Heart failure patients with RBCM deficit or true anemia demonstrated poorer exercise capacity.
“This research from Duke University provides additional compelling evidence for the value of BVA in heart failure management,” said John L. Jefferies, MD, MPH, MBA, Daxor's Chief Medical Officer. “The ability to differentiate between true and dilutional pseudo-anemia fundamentally changes a patient’s treatment approach. Accurate volume status directly impacts therapeutic decisions, patient outcomes and quality of life, and reinforces why blood volume measurement should be standard in comprehensive heart failure care."
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 70,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What did the Duke University study reveal about Daxor's (DXR) Blood Volume Analysis technology?
How does Daxor's (DXR) Blood Volume Analysis impact heart failure patient outcomes?
What percentage of heart failure patients have true vs. pseudo-anemia according to Daxor's (DXR) study?
Why is Daxor's (DXR) Blood Volume Analysis important for heart failure treatment?
